ANTX vs GALT
ANTX: AN2 Therapeutics leverages a proprietary boron chemistry platform to develop small-molecule drugs for neglected infectious diseases, blood cancers, and other high-unmet-need conditions. GALT: Clinical-stage biopharmaceutical company developing galectin-3 inhibitors derived from plant carbohydrates to treat liver fibrosis, cirrhosis, and cancer.
Side-by-side fundamentals
| Metric | ANTX | GALT | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $5.33 | $3.38 | |
| Market cap as of 2026-07-31 | $192M | $230M | |
| ROE as of 2026-07-31 | -52.3% | -258.6% | ANTX higher |
| ROA as of 2026-07-31 | -47.3% | -164.7% | ANTX higher |
| Debt / equity as of 2026-07-31 | 0.00 | 11.09 | ANTX lower |
| Beta as of 2026-07-31 | 0.70 | 0.41 | |
| 1-year return as of 2026-07-30 close | +398.1% | +16.2% | ANTX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.